Shares of Xeris Pharmaceuticals Inc (XERS) soared 5.33% in the pre-market session on Friday, following analysts raising their price targets on the stock.
Piper Sandler raised its price target on Xeris Biopharma to $4 from $3, while maintaining a Neutral rating. H.C. Wainwright also boosted its price target to $8 from $6.60 and reiterated a Buy rating on the shares.
The positive analyst actions reflect optimism around Xeris Pharmaceuticals' prospects, driving the stock's significant upward movement during this morning's trading session.